Genetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)
Customize your policy alerts
Sign up for Capital Bluecross Policy 2.246 alerts
Get alerted when Policy 2.246 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage stance for germline genetic testing for genes associated with familial cutaneous malignant melanoma (notably CDKN2A and CDK4) for Capital BlueCross members and explains rationale and related guidelines for use.
Policy statement changed to investigational (INV).
Procedure code 81403 was added to the coding table.
Policy title was updated (formerly 'Germline Genetic Testing for Familial Cutaneous Malignant Melanoma').
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.